0001811115falseX0true0001811115rnlx:AmericanDepositarySharesMember2023-10-182023-10-1800018111152023-10-182023-10-18

 

 

 

 

 

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 18, 2023

 

Renalytix plc

(Exact name of registrant as specified in its Charter)

 

England and Wales

001-39387

Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Finsgate

5-7 Cranwood Street

London EC1V 9EE

United Kingdom

(Address of principal executive offices) (Zip Code)

+44 20 3139 2910
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Ordinary shares, nominal value £0.0025 per ordinary share

n/a

The Nasdaq Stock Market LLC*

American Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per ordinary share

RNLX

The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On October 18, 2023, Mr. Timothy J. Scannell submitted notice of his resignation from the board of directors (the “Board”) of Renalytix plc (the “Company”), which resignation was effective immediately. Mr. Scannell’s resignation was not the result of any disagreement with the Company or the Board.

Item 9.01. Exhibits.

(d) Exhibits

Exhibit No.

Description

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Renalytix plc

 

 

 

Dated: October 24, 2023

By:

/s/ James McCullough

 

 

James McCullough
Chief Executive Officer

 

 

v3.23.3
Document And Entity Information
Oct. 18, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 18, 2023
Entity Registrant Name Renalytix plc
Entity Central Index Key 0001811115
Securities Act File Number 001-39387
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Finsgate
Entity Address, Address Line Two 5-7 Cranwood Street
Entity Address, City or Town London
Entity Address, Country GB
Entity Address, Postal Zip Code EC1V 9EE
City Area Code +44
Local Phone Number 20 3139 2910
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary shares, nominal value £0.0025 per ordinary share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per ordinary share
Trading Symbol RNLX
Security Exchange Name NASDAQ
Renalytix (NASDAQ:RNLX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024 Haga Click aquí para más Gráficas Renalytix.
Renalytix (NASDAQ:RNLX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024 Haga Click aquí para más Gráficas Renalytix.